REMEGEN's stock plummeted 5.19% intraday, extending a high-level correction as recent positive developments appear to have been fully absorbed by the market.

The decline follows significant catalysts, including a $650 million upfront payment from AbbVie under an exclusive licensing agreement for the bispecific antibody drug RC148 and the presentation of core data from its novel PR-ADC payload recovery platform at a major medical conference. However, with the A-share counterpart having surged substantially in the prior week and southbound capital persistently reducing holdings, traders are engaging in profit-taking.

The movement reflects a market view that prior gains were substantial and multiple positive catalysts have now been fully digested, leading to a technical pullback from recent highs.